Pre-meeting symposium:

Symposium on Malignant Skin Inflammation

Wednesday, November 12, 2025

Location: New York Academy of Medicine, New York City, NY, USA

 

Primary cutaneous lymphomas often pose diagnostic challenges due to their resemblance to benign inflammatory skin diseases. This symposium is dedicated to this topic, and an excellent group of international leaders in the field will be present, who will share their data and opinions on the role of chronic inflammation in primary cutaneous lymphomas. Spots will also be reserved for abstract submitters who want to present their data.

 

Program

09:00 AM – 09:10 AM Welcome and Introduction
09:10 AM – 09:30 AM Patrick M. Brunner, New York, USA
Chronic inflammation – lessons learned from CTCL
09:30 AM – 09:50 AM Shamir Geller, New York, USA
Development of cutaneous T-cell lymphoma in patients with skin inflammatory diseases – the roles of chronic stimulation and drug induced immuno-modulation
09:50 AM – 10:10 AM Sima Rozati, Baltimore, USA
From inflammation to malignancy: Dissecting clinical with molecular links
10:10 AM – 10:30 AM Emmanuella Guenova, Linz, Austria
Decoding Escape Mechanisms in Cutaneous T-Cell Lymphomas: From HLA-I Aberrations to Therapeutic Synergies
10:30 AM – 10:50 AM Larisa Geskin, New York, USA
Paradigm shift: What PCMZL teaches us about chronic inflammation
10:50 AM – 11:30 AM Oral Presentations from Selected Abstracts

  • Co-existing malignant subclones maintain a balance between Staphylococcus aureus-induced aggressiveness and intrinsic drug resistance in cutaneous T-cell lymphoma (Terkild Brink Buus, Copenhagen, Denmark)

  • Predicting response to topical chlormethine treatment in early-stage Mycosis Fungoides: optical coherence tomography vs. histology (Robert Rissmann, Leiden, The Netherlands)

  • Spatial profiling of CD8+ T cells and macrophages in the skin of patients with mycosis fungoides (Hanna Brauner, Stockholm, Sweden)
11:30 AM – 11:50 AM Lunch Break
11:50 AM – 12:10 PM Neda Nikbakht, Atlanta, USA
Preclinical Evaluation of Macrophage Reprogramming in Treatment of CTCL
12:10 PM – 12:30 PM Evengelia Papadavid, Athens, Greece
Decoding the TME from patch to tumor in mycosis fungoides
12:30 PM – 12:50 PM Sergei Koralov, New York, USA
How Do Microbe-Derived Cues Shape CTCL Tumor Evolution?
12:50 PM – 01:10 PM Christiane Querfeld, Duarte, USA
Immune checkpoints in the CTCL tumor microenvironment
01:10 PM – 01:30 PM Michael Girardi, New Haven, USA
Personalized Immunotherapeutics for CTCL
01:30 PM – 01:50 PM Oleg Akilov, Pittsburgh, USA
Two Front War: Rational Dual Targeting of Malignant Cells and Their Immunologic Shelter
01:50 PM – 02:00 PM Concluding remarks